<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00544349</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000564063</org_study_id>
    <secondary_id>FRE-IGR-CHOICE</secondary_id>
    <secondary_id>IGR-1207</secondary_id>
    <secondary_id>INCA-RECF0449</secondary_id>
    <nct_id>NCT00544349</nct_id>
  </id_info>
  <brief_title>Leucovorin, Fluorouracil, Cetuximab, and Oxaliplatin in Treating Patients With Stage IV Colorectal Cancer and Liver Metastases That Cannot Be Removed by Surgery</brief_title>
  <official_title>Phase II Study Evaluating the Effectiveness of the Association of Chemotherapy LV5FU2 Simplified and Cetuximab With Intra-arterial Hepatic Chemotherapy Using Oxaliplatin in Patients With Colorectal Cancer and Nonresectable Hepatic Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as leucovorin, fluorouracil, and oxaliplatin,&#xD;
      work in different ways to stop the growth of tumor cells, either by killing the cells or by&#xD;
      stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth&#xD;
      in different ways. Some block the ability of tumor cells to grow and spread. Others find&#xD;
      tumor cells and help kill them or carry tumor-killing substances to them. Giving more than&#xD;
      one drug (combination chemotherapy) and giving them together with cetuximab may kill more&#xD;
      tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving leucovorin together with&#xD;
      fluorouracil, cetuximab, and oxaliplatin works in treating patients with stage IV colorectal&#xD;
      cancer and liver metastases that cannot be removed by surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the efficacy of this regimen by the measurement of objective response rate&#xD;
           (RECIST criteria).&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the toxicity of this regimen.&#xD;
&#xD;
        -  Evaluate the duration of tumor response.&#xD;
&#xD;
        -  Determine the duration and rate of tumor control.&#xD;
&#xD;
        -  Determine the rate of secondary resectability of hepatic metastases.&#xD;
&#xD;
        -  Evaluate progression-free survival&#xD;
&#xD;
        -  Determine rate of progression of the tumor.&#xD;
&#xD;
        -  Determine overall survival.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive cetuximab IV over 1 hour, leucovorin calcium IV over 2 hours, and&#xD;
      fluorouracil IV continuously over 46 hours. Patients also receive oxaliplatin by hepatic&#xD;
      arterial infusion over 2 hours. Treatment continues for at least 3 months in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: objective tumor response rate (RECIST criteria)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity as assessed by NCI CTCAE v3.0</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration and rate of tumor control</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary resectability of hepatic metastases</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor progression rate</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cetuximab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed primary cancer of the colon or rectum&#xD;
&#xD;
               -  Isolated hepatic metastases&#xD;
&#xD;
               -  Not amenable to curative resection or requirement for complex and or larger&#xD;
                  (i.e., &gt; 4 liver segments) liver resection&#xD;
&#xD;
          -  Measurable disease (RECIST criteria)&#xD;
&#xD;
          -  Original tumor must be (or have been) removed&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  WHO performance status 0-1&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  ANC ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times normal&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal&#xD;
&#xD;
          -  Transaminases ≤ 5 times normal&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Contraindication or allergy grade 3-4 to any components of the study drugs&#xD;
&#xD;
          -  Peripheral neuropathy&#xD;
&#xD;
          -  Intestinal occlusion or subocclusion or prior inflammatory intestinal disease&#xD;
&#xD;
          -  Severe cardiac disease including any of the following:&#xD;
&#xD;
               -  Symptomatic coronary disease&#xD;
&#xD;
               -  Myocardial infarction in the past 6 months&#xD;
&#xD;
               -  New York Heart Association grade II-IV cardiac insufficiency&#xD;
&#xD;
               -  Severe arrhythmia (even if treated)&#xD;
&#xD;
          -  Active or uncontrolled infection&#xD;
&#xD;
          -  Other concurrent serious disorder&#xD;
&#xD;
          -  Severe uncontrolled medical condition&#xD;
&#xD;
          -  Other malignancy within the past 5 years or concurrently except basal cell skin cancer&#xD;
             or carcinoma in situ of the cervix&#xD;
&#xD;
          -  Study impossible due to psychological, geographical, or social reasons&#xD;
&#xD;
          -  Prisoners or patients under guardianship&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Prior chemotherapy except adjuvant chemotherapy comprising fluorouracil, leucovorin&#xD;
             calcium, capecitabine, oxaliplatin, irinotecan hydrochloride, and/or bevacizumab&#xD;
             (completed &gt; 6 months ago if oxaliplatin- or irinotecan-based)&#xD;
&#xD;
          -  Prior epidermal growth factor (EGF), monoclonal antibody inhibiting transduction of&#xD;
             EGF receptor (EGFR), or any other treatment targeting the EGFR&#xD;
&#xD;
          -  Other concurrent anticancer immunotherapy, chemotherapy, or hormone therapy&#xD;
&#xD;
          -  Participation in another study in the past 30 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Malka, MD, PhD</last_name>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Saint Andre</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Lutte Contre le Cancer Georges-Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Pitie-Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugene Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35062</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Paul Brousse</name>
      <address>
        <city>Villejuif</city>
        <zip>94804</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>F-94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <study_first_submitted>October 13, 2007</study_first_submitted>
  <study_first_submitted_qc>October 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2007</study_first_posted>
  <last_update_submitted>May 14, 2011</last_update_submitted>
  <last_update_submitted_qc>May 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 17, 2011</last_update_posted>
  <keyword>stage IV colon cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>liver metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

